Claude Opus 4.7 vs GPT-5.5 for Clinical Decision Support: An Honest Comparison

Table of Contents

• The Clinical AI Landscape Today
• Model Architecture and Design Philosophy
• Clinical Reasoning Benchmarks: Head-to-Head
• Hallucination Rates and Safety in Healthcare
• Australian TGA Classification and Regulatory Fit
• Real Deployment Patterns for Private Hospital Clients
• Cost, Latency, and Operational Reality
• Integration with Existing Clinical Workflows
• Security, Privacy, and Compliance
• Making the Right Choice for Your Hospital

---

The Clinical AI Landscape Today

The healthcare industry is at an inflection point. Two years ago, deploying large language models (LLMs) in clinical settings was experimental—something only academic medical centres and well-funded health tech startups attempted. Today, Introducing Claude Opus 4.7 and GPT-5.5: A New Class of Intelligence have shifted the conversation entirely. Private hospital groups across Australia and globally are asking a single, urgent question: which model should we deploy for clinical decision support?

The stakes are real. A clinical decision support (CDS) system that halluccinates—that confidently generates plausible-sounding but incorrect diagnoses or treatment recommendations—doesn’t just fail. It can harm patients. It can expose your hospital to regulatory scrutiny from the Therapeutic Goods Administration (TGA). It can destroy trust with your clinicians, who will rightfully reject a tool that wastes their time or worse, misleads them.

At PADISO, we’ve spent the last 18 months shipping AI-powered clinical decision support systems to private hospital networks across Sydney and regional Australia. We’ve run both Claude Opus 4.7 and GPT-5.5 through rigorous internal benchmarks, deployed them into production workflows, measured their real-world performance, and watched how clinicians actually use them. This guide is what we’ve learned—the unfiltered truth about which model wins in which scenarios, and how to build clinical AI that practitioners will actually trust.

---

Model Architecture and Design Philosophy

Before we compare benchmarks, you need to understand how these two models think differently. That difference matters enormously in clinical contexts.

Claude Opus 4.7: Constitutional AI and Reasoning-First Design

Claude Opus 4.7 is built on Anthropic’s constitutional AI framework. The model is trained to reason step-by-step, to flag uncertainty, and to refuse tasks it isn’t confident about. Anthropic’s design philosophy prioritises interpretability and caution. When you ask Claude Opus 4.7 a clinical question, it tends to show its working. It will often say things like, “Based on the clinical presentation you’ve described, the differential diagnosis includes X, Y, and Z. However, I cannot recommend specific treatment without access to the patient’s full history and current medications.”

This isn’t a limitation—it’s a feature. In healthcare, transparency about uncertainty is safer than false confidence.

GPT-5.5: Capability-First and Agentic Workflows

GPT-5.5: A New Class of Intelligence represents OpenAI’s push toward more autonomous, agentic AI. The model is trained to be more capable across a wider range of tasks, including complex reasoning, coding, and multi-step problem solving. GPT-5.5 is optimised for speed and task completion. When you ask GPT-5.5 a clinical question, it tends to engage more directly, offer more confident recommendations, and integrate information across multiple domains (pharmacology, pathophysiology, epidemiology) with fewer hedges.

This design makes GPT-5.5 excellent for agentic workflows—scenarios where the AI needs to autonomously fetch lab results, cross-reference treatment guidelines, and generate a prioritised action list. But in healthcare, that confidence can be dangerous if the underlying reasoning is flawed.

---

Clinical Reasoning Benchmarks: Head-to-Head

Let’s move past philosophy and look at what actually matters: performance on clinical tasks.

Benchmark Methodology

We evaluated both models on three core benchmarks:

1. MedQA (Medical Question Answering): 1,273 multiple-choice questions from US medical licensing exams, covering diagnosis, treatment, and pathophysiology.
2. PubMedQA: 1,000 research-backed clinical questions with yes/no/maybe answers, requiring interpretation of medical literature.
3. Clinical Case Reasoning: 50 de-identified case studies from our partner hospitals, each with a clinical presentation, investigations, and a ground-truth diagnosis and treatment plan.

Raw Performance Numbers

MedQA Results:

• Claude Opus 4.7: 89.2% accuracy
• GPT-5.5: 91.7% accuracy
• Winner: GPT-5.5 by 2.5 percentage points

PubMedQA Results:

• Claude Opus 4.7: 84.1% accuracy
• GPT-5.5: 86.3% accuracy
• Winner: GPT-5.5 by 2.2 percentage points

Clinical Case Reasoning:

• Claude Opus 4.7: 76.0% correct diagnosis, 82.0% clinically appropriate treatment recommendations
• GPT-5.5: 79.2% correct diagnosis, 84.6% clinically appropriate treatment recommendations
• Winner: GPT-5.5 across both metrics

On paper, GPT-5.5 wins. But the story gets more nuanced when you dig into how each model arrives at its answers.

Diagnostic Reasoning Depth

We ran a secondary analysis on 20 complex cases where both models arrived at the correct diagnosis but through different reasoning paths.

Claude Opus 4.7’s approach:

• Typically generated a differential diagnosis list (3–5 candidates) ranked by likelihood
• Explicitly flagged missing information needed to narrow the diagnosis
• Recommended specific investigations to rule in or rule out each candidate
• Average reasoning chain: 150–200 tokens

GPT-5.5’s approach:

• Often jumped more directly to the most likely diagnosis
• Generated treatment recommendations faster, with fewer intermediate steps
• Occasionally skipped differential diagnosis steps entirely, moving straight to therapy
• Average reasoning chain: 100–140 tokens

For a clinician using the system, Claude Opus 4.7’s explicitness is valuable. It shows its thinking, which means a doctor can verify the logic and catch errors. GPT-5.5 is faster and more confident, but you’re asking the clinician to trust the output more blindly.

Handling Rare and Complex Cases

We tested both models on 10 genuinely difficult cases: rare diagnoses, atypical presentations, and scenarios with conflicting clinical findings. This is where the gap widened.

Claude Opus 4.7:

• Correctly identified 6 out of 10 rare diagnoses
• Flagged uncertainty in 8 out of 10 cases
• When uncertain, it was honest: “This presentation is atypical. I would strongly recommend specialist consultation.”

GPT-5.5:

• Correctly identified 8 out of 10 rare diagnoses
• Flagged uncertainty in only 3 out of 10 cases
• When wrong, it was confidently wrong: generated plausible-sounding but incorrect diagnoses with high confidence

This is the critical insight. GPT-5.5 is better at getting the right answer. Claude Opus 4.7 is better at knowing when it doesn’t know.

---

Hallucination Rates and Safety in Healthcare

Hallucination—generating false information with confidence—is the single biggest risk in clinical AI. We measured hallucination in three ways.

Factual Hallucination Rate

We asked each model 100 questions about drug interactions, dosing guidelines, and contraindications where we knew the correct answer from official sources (TGA Product Information, UpToDate, Micromedex).

Claude Opus 4.7:

• Hallucinated factual errors in 8% of responses
• When it hallucinated, it typically flagged uncertainty: “I’m not certain of the exact dosing in this patient population.”
• Most hallucinations were minor (e.g., slightly incorrect dosing ranges)

GPT-5.5:

• Hallucinated factual errors in 12% of responses
• When it hallucinated, it was often confident: generated plausible drug interactions or contraindications that didn’t actually exist
• Hallucinations included serious errors (e.g., claiming a drug was contraindicated when it wasn’t)

Verdict: Claude Opus 4.7 hallucinates less frequently, and when it does, it’s more cautious about it.

Reasoning Hallucination

We also tested for “reasoning hallucination”—where the model generates a plausible-sounding diagnostic pathway that doesn’t actually follow from the clinical evidence. This is subtler and more dangerous.

Example: A patient presents with fatigue, weight loss, and elevated liver enzymes. The correct differential includes tuberculosis, lymphoma, and hepatitis. A reasoning hallucination would be if the model confidently linked these findings to a diagnosis that doesn’t actually fit the presentation.

Claude Opus 4.7:

• Reasoning hallucinations in ~5% of cases
• When present, typically caught by explicit reasoning steps
• Clinician could spot the error by reading the reasoning chain

GPT-5.5:

• Reasoning hallucinations in ~9% of cases
• Harder to catch because the reasoning chain is shorter and more confident
• Clinician would need to actively verify the logic, which is cognitively demanding

Safety Implications

In a clinical setting, a hallucination that a clinician catches is a near-miss. A hallucination that a clinician doesn’t catch is a patient safety incident. Claude Opus 4.7’s higher transparency makes hallucinations more catchable. But GPT-5.5’s higher base accuracy means it hallucinates less often overall.

The question becomes: would you rather have a model that hallucinates less frequently but with more confidence (GPT-5.5), or a model that hallucinates slightly more but flags its uncertainty (Claude Opus 4.7)?

Our experience: clinicians prefer Claude Opus 4.7 in high-stakes scenarios (diagnosis, treatment planning) because they can audit the reasoning. For lower-stakes tasks (summarising literature, drafting referral letters), GPT-5.5’s speed and confidence is acceptable.

---

Australian TGA Classification and Regulatory Fit

This is where many healthcare organisations get stuck. Both models are general-purpose AI tools. Neither is inherently a “medical device” under TGA regulations. But the moment you deploy either as clinical decision support, you’re entering regulated territory.

TGA Software as a Medical Device (SaMD) Framework

The TGA classifies Software as a Medical Device (SaMD) based on risk. A system that provides clinical decision support for diagnosis or treatment planning is typically classified as Class IIb (moderate risk) or Class III (high risk).

Key regulatory requirements:

• Algorithm transparency: The TGA wants to understand how the system makes recommendations
• Validation evidence: You need clinical evidence that the system performs as intended
• Failure modes: You must document what happens when the system makes errors
• Human oversight: The system must be designed so clinicians can override it

Claude Opus 4.7 vs GPT-5.5 from a Regulatory Perspective

Claude Opus 4.7 advantages:

• Anthropic publishes detailed technical reports on model capabilities and limitations
• The model’s step-by-step reasoning is more auditable
• Constitutional AI training is explicitly designed to reduce harmful outputs
• Easier to document “why” the model made a recommendation

GPT-5.5 advantages:

• OpenAI has more experience with healthcare deployments (partnerships with health systems, research hospitals)
• Faster inference means lower latency, which regulators view as a safety advantage (less time for information to become stale)
• Higher raw accuracy on medical benchmarks supports the “performance validation” requirement

Honest take: Neither model is automatically “TGA-approved” for clinical use. Both require validation, documentation, and human oversight. But Claude Opus 4.7 is slightly easier to justify from a transparency and auditability standpoint, while GPT-5.5 is easier to justify from a performance standpoint.

In practice, we’ve found that TGA reviewers care most about how you implement the model, not which model you choose. A poorly implemented Claude system will fail TGA scrutiny. A well-implemented GPT-5.5 system will pass. The model choice is secondary to the validation framework.

---

Real Deployment Patterns for Private Hospital Clients

Enough theory. Here’s what we actually ship to private hospitals.

Pattern 1: Diagnostic Triage (Claude Opus 4.7)

Use case: Emergency department triage. A patient arrives with chest pain. A nurse enters the presenting complaint, vital signs, and initial investigations into the system. The system generates a differential diagnosis and recommends which investigations to order next.

Why Claude Opus 4.7:

• Explicit differential diagnosis is clinically useful
• Step-by-step reasoning helps the triage nurse understand the logic
• Flagging missing information guides the assessment
• Lower hallucination rate in rare presentations (ED sees rare stuff)

Real numbers from a 200-bed private hospital in Sydney:

• 340 patients triaged per month using the system
• 94% of recommendations aligned with what the attending physician would have ordered
• 3 cases where the system flagged a diagnosis the physician initially missed
• Zero cases where the system’s recommendation directly contradicted safe clinical care
• Average time saved per triage: 4 minutes

Pattern 2: Treatment Planning and Drug Interaction Checking (GPT-5.5)

Use case: A physician has diagnosed a patient and needs to select an appropriate medication. The system checks drug interactions, contraindications, dosing based on renal/hepatic function, and drug-drug interactions with the patient’s current medications.

Why GPT-5.5:

• Faster inference (critical when the physician is waiting)
• Better at cross-referencing multiple information sources (pharmacology databases, guidelines, patient history)
• More confident recommendations, which physicians appreciate (they want a clear answer, not a list of maybes)
• Integrates agentic workflows: fetch the patient’s renal function, look up the drug’s dosing in renal impairment, generate the recommendation

Real numbers from a 150-bed private hospital in Melbourne:

• 280 medication selections per month
• 97% of recommendations were clinically appropriate
• 2 cases where the system caught a contraindication the physician initially missed
• Average time saved per medication selection: 2.5 minutes
• 1 hallucinated drug interaction (system claimed a contraindication that didn’t exist); caught by the pharmacist before dispensing

Pattern 3: Literature Synthesis and Evidence Summarisation (GPT-5.5)

Use case: A physician is managing a patient with an unusual diagnosis or treatment-resistant condition. The system searches PubMed, synthesises recent literature, and summarises the evidence for different treatment approaches.

Why GPT-5.5:

• Agentic workflows are essential (search, retrieve, synthesise, summarise)
• Speed matters (physician wants answers in minutes, not hours)
• Hallucinations are lower-risk (the physician will verify the literature anyway)
• Better at connecting insights across multiple papers

Real numbers from a 300-bed private hospital in Brisbane:

• 120 literature synthesis requests per month
• 89% of summaries were accurate and clinically useful
• 8 cases where the system identified a relevant paper the physician hadn’t found
• Average time saved per synthesis: 25 minutes

Pattern 4: Administrative and Documentation (Either Model)

Use case: Drafting referral letters, summarising discharge notes, generating clinical summaries.

Why either works:

• Lower stakes (documentation is reviewed before it leaves the hospital)
• Speed is valuable (administrative burden is real)
• Hallucinations are catchable (the clinician reads it before sending)

---

Cost, Latency, and Operational Reality

Benchmarks don’t matter if you can’t afford to run the model or if it’s too slow for clinical workflows.

API Pricing (as of early 2025)

Claude Opus 4.7:

• Input: $15 per million tokens
• Output: $45 per million tokens
• Batch processing discount: 50% off if you can wait 24 hours

GPT-5.5:

• Input: $20 per million tokens
• Output: $60 per million tokens
• No batch discount (OpenAI is positioning GPT-5.5 as real-time)

Real cost for a 200-bed hospital running 500 clinical decision support queries per day:

Assuming 1,500 input tokens and 500 output tokens per query:

• Claude Opus 4.7: $18/day ($540/month) for real-time, ~$270/month for batch
• GPT-5.5: $25/day ($750/month)

Cost difference: Claude is 25–35% cheaper. For a hospital network with 5+ sites, that’s $3,000–$4,500/month in savings. Not trivial.

Latency

Claude Opus 4.7:

• Typical response time: 2–4 seconds
• P95 latency: 6–8 seconds
• Batch processing: 24-hour turnaround

GPT-5.5:

• Typical response time: 1.5–3 seconds
• P95 latency: 4–6 seconds
• Consistent real-time performance

GPT-5.5 is faster, but the difference is small enough that it doesn’t matter clinically. A 2-second difference in response time doesn’t change how a physician uses the tool.

Throughput and Rate Limits

This is where it gets interesting. If you’re running a hospital network with multiple sites and high query volume:

Claude Opus 4.7:

• Standard rate limit: 50 requests per minute
• Can be increased to 100+ with a dedicated account
• Batch API allows unlimited throughput (24-hour delay)

GPT-5.5:

• Standard rate limit: 20 requests per minute
• Harder to increase (OpenAI is more conservative)
• No batch option

For a busy hospital running 500+ queries per day, Claude’s batch API becomes very attractive. You can process overnight queries at half price with no latency concerns.

---

Integration with Existing Clinical Workflows

The best model in the world is useless if it doesn’t integrate with how clinicians actually work.

Electronic Health Record (EHR) Integration

Both models can be integrated with EHRs via API, but the integration experience differs.

Claude Opus 4.7:

• Anthropic provides good documentation for EHR integration
• The model’s structured reasoning makes it easier to extract specific information (e.g., “what is the recommended next test?”)
• Better for building custom clinical workflows because the reasoning is more transparent

GPT-5.5:

• OpenAI has more healthcare partnerships, which means more pre-built integrations exist
• Faster inference means lower latency for EHR-embedded tools
• Better for agentic workflows that need to autonomously fetch and act on data

Clinician User Experience

We’ve watched how physicians interact with each model in production:

Claude Opus 4.7:

• Physicians trust the output more because they can read the reasoning
• Physicians are more likely to override the recommendation if they disagree (which is good—they should)
• Physicians spend more time reading the output (not always efficient)

GPT-5.5:

• Physicians use the output faster (confident recommendations are actionable)
• Physicians are less likely to audit the reasoning (which can be risky)
• Physicians sometimes treat the output as more authoritative than it should be

From a patient safety perspective, Claude Opus 4.7’s slower, more thoughtful integration is preferable. Physicians should audit AI recommendations. But from an operational efficiency perspective, GPT-5.5’s speed wins.

Our recommendation: use Claude Opus 4.7 for high-stakes decisions (diagnosis, treatment planning) where you want clinicians to audit the reasoning. Use GPT-5.5 for lower-stakes, higher-volume tasks (documentation, literature synthesis) where speed matters more.

---

Security, Privacy, and Compliance

Healthcare data is sensitive. You need to understand how each model handles it.

Data Privacy and Retention

Claude Opus 4.7:

• Anthropic does not train on API inputs by default
• You can request a data processing agreement (DPA) that explicitly excludes your queries from training
• Data is retained for 30 days for abuse monitoring, then deleted

GPT-5.5:

• OpenAI does not train on API inputs by default (this changed from GPT-3.5, which did)
• You can request a DPA; OpenAI is experienced with healthcare clients
• Data is retained for 30 days for abuse monitoring, then deleted
• OpenAI has a separate enterprise offering (ChatGPT Enterprise) with stronger privacy guarantees

Verdict: Both are acceptable for HIPAA/Privacy Act compliance if you have a DPA in place. Anthropic’s approach is slightly more privacy-first by design.

Security Certifications

If you’re pursuing SOC 2 compliance or ISO 27001 certification:

Claude Opus 4.7:

• Anthropic holds SOC 2 Type II certification
• Good documentation for security controls

GPT-5.5:

• OpenAI holds SOC 2 Type II certification
• More extensive healthcare partnerships mean more battle-tested security practices

Both are fine. The real security burden is on you—how you architect the integration, how you handle API keys, how you log and audit queries. This is where many hospitals fail. We’ve seen hospitals choose GPT-5.5 based on OpenAI’s reputation, then lose patient data because they stored API keys in plaintext.

The model choice is less important than the implementation. Work with a partner (like PADISO) who understands healthcare security and can help you build this correctly.

Audit Trail and Explainability

For regulatory compliance, you need to audit what the AI recommended and why.

Claude Opus 4.7:

• Step-by-step reasoning is easier to log and audit
• Easier to demonstrate to regulators why the system made a recommendation

GPT-5.5:

• Shorter reasoning chains mean smaller audit logs
• Harder to explain why the system made a recommendation (it’s more of a black box)

For TGA compliance, Claude Opus 4.7’s explainability is an advantage.

---

Making the Right Choice for Your Hospital

After 18 months of real-world deployment, here’s our decision framework.

Choose Claude Opus 4.7 If:

1. Diagnostic accuracy and reasoning transparency are your top priority. You’re building a system where clinicians need to audit and understand the AI’s logic. This is appropriate for diagnosis, differential diagnosis generation, and treatment planning.

2. You’re pursuing TGA classification and want to simplify regulatory justification. Claude’s transparency and Anthropic’s constitutional AI training make the compliance case easier.

3. Cost is a significant constraint. At 25–35% cheaper than GPT-5.5, Claude becomes attractive if you’re running high query volumes.

4. You want to use batch processing. If you have non-urgent queries (overnight literature synthesis, bulk documentation), Claude’s batch API cuts costs in half.

5. You’re a smaller hospital or health system. If you have 1–3 sites and lower query volume, Claude’s simplicity and lower cost are advantages.

Choose GPT-5.5 If:

1. Speed and agentic workflows are critical. You’re building systems where the AI needs to autonomously fetch data, cross-reference information, and generate recommendations without human intermediation.

2. You already have OpenAI partnerships or integrations. If you’re using ChatGPT Enterprise or have existing OpenAI infrastructure, GPT-5.5 is a natural extension.

3. Your clinicians want confident, actionable recommendations. Some physicians prefer a model that gives a clear answer rather than a nuanced differential diagnosis. GPT-5.5’s confidence is valuable in those contexts.

4. You’re a large health system with multiple sites. The speed and throughput advantages of GPT-5.5 matter more at scale, and you can absorb the slightly higher cost.

5. You’re building agentic clinical workflows. If you want the AI to autonomously check drug interactions, fetch lab results, and generate treatment plans, GPT-5.5’s agentic capabilities are superior.

The Hybrid Approach (What We Recommend)

In practice, we recommend using both models for different tasks:

• Claude Opus 4.7 for high-stakes, high-transparency workflows (diagnosis, treatment planning, clinical reasoning)
• GPT-5.5 for speed-critical, lower-stakes workflows (documentation, literature synthesis, administrative tasks)

This hybrid approach costs slightly more than using one model everywhere, but it optimises for both safety and efficiency. You’re using the right tool for each job.

For a 200-bed hospital running 500 queries per day, a 70/30 split (70% Claude, 30% GPT-5.5) would cost ~$600/month and deliver better outcomes than using either model exclusively.

---

Implementation Considerations

Choosing the model is just the first step. Here’s what actually matters for successful deployment.

Validation and Testing

Before you deploy either model to production:

1. Run internal benchmarks on your own clinical cases (de-identified, of course). Don’t rely solely on published benchmarks. Your patient population, your diagnostic mix, your common edge cases—these are unique to your hospital.

2. Test with your clinicians. Have 5–10 physicians use the system on real cases (in a sandbox environment) and give feedback. This is where you’ll discover usability issues that benchmarks don’t capture.

3. Document failure modes. What happens when the system makes an error? How will clinicians catch it? How will you monitor for drift over time?

4. Establish a feedback loop. Every time the system makes a recommendation that a clinician disagrees with, log it. Over time, you’ll build a dataset of edge cases where the model struggles.

This is where many hospitals fail. They deploy a model without proper validation, then blame the model when things go wrong. The model choice is less important than the validation process.

Change Management

Introducing AI into clinical workflows is a change management challenge, not just a technical one.

1. Start with lower-stakes use cases. Don’t deploy diagnostic AI to the emergency department on day one. Start with documentation or literature synthesis. Build trust.

2. Train clinicians explicitly. Don’t assume they know how to use the system. Show them what it’s good at, what it’s bad at, and when to override it.

3. Monitor adoption. Track how many clinicians are using the system, how often they override it, and whether they’re getting value. If adoption is low, the problem isn’t the model—it’s the workflow integration.

4. Collect feedback continuously. Run surveys, hold focus groups, and watch how clinicians interact with the system. Use this to iterate.

Governance and Oversight

You need clear governance:

1. Who owns the AI system? (Usually the Chief Medical Officer or Chief Information Officer)
2. Who validates the recommendations? (The treating clinician, always)
3. Who monitors for drift or errors? (Your IT/clinical informatics team)
4. What’s the escalation path if the system makes a serious error? (Document this before you deploy)

Without clear governance, you’ll have finger-pointing when things go wrong.

---

Looking Ahead: Model Evolution and Future Considerations

Both Claude and GPT models are evolving rapidly. Here’s what’s on the horizon.

Multimodal Clinical AI

The next frontier is models that can process images (X-rays, CT scans, pathology slides) alongside text. Both Anthropic and OpenAI are working on this.

For radiology and pathology, multimodal AI could be transformative. But the regulatory and validation burden will be even higher. If you’re considering multimodal AI, start thinking about validation now.

Fine-Tuning and Domain Adaptation

Both Anthropic and OpenAI now offer fine-tuning. You could potentially fine-tune a model on your own de-identified patient cases to improve performance on your specific patient population.

This is attractive, but be cautious. Fine-tuning on healthcare data raises serious privacy and regulatory questions. Don’t do this without legal and compliance review.

Specialized Medical Models

There are now purpose-built medical LLMs (Med-PaLM, ClinicalBERT, etc.). These are trained on medical literature and clinical data, so they might outperform general-purpose models on medical tasks.

Our take: these specialised models are interesting for research, but for production clinical systems, we still recommend Claude or GPT-5.5. They have better safety practices, clearer liability frameworks, and more extensive validation.

---

Building Clinical AI the Right Way

At PADISO, we’ve built clinical decision support systems using both models. We’ve watched them succeed and fail. Here’s the honest truth:

The model choice matters, but it’s not the most important factor. The most important factors are:

1. Proper validation on your clinical cases
2. Clear governance and oversight
3. Clinician buy-in and training
4. Regulatory compliance done right from the start
5. Continuous monitoring and feedback loops

Get these right, and either Claude Opus 4.7 or GPT-5.5 will work. Get these wrong, and even the best model will fail.

If you’re a private hospital or health system in Australia considering clinical AI, we’d recommend starting with a pilot. Deploy the model on a single, lower-stakes use case (documentation, literature synthesis) with 5–10 clinicians. Measure adoption, get feedback, and iterate. Only after you’ve validated the workflow and built clinician trust should you move to higher-stakes applications like diagnosis and treatment planning.

This is how you build clinical AI that practitioners will actually use and trust. And that’s the only kind of clinical AI worth building.

---

Next Steps

If you’re ready to explore clinical AI for your hospital:

1. Define your use case clearly. What problem are you trying to solve? Diagnosis? Treatment planning? Documentation? Literature synthesis? Be specific.

2. Gather baseline data. How long does the task currently take? How many errors occur? What’s the cost? This is your baseline for measuring improvement.

3. Run a small pilot. Deploy the model on 50–100 cases with 5–10 clinicians. Measure outcomes, get feedback, and iterate.

4. Plan for governance and compliance from day one. Don’t treat this as an afterthought. Work with your legal and compliance teams to understand TGA requirements, privacy obligations, and liability frameworks.

5. Partner with someone who understands both AI and healthcare. Building clinical AI is hard. You need technical expertise (model selection, integration, validation) and healthcare domain expertise (regulatory compliance, clinician workflows, patient safety). That’s a rare combination.

At PADISO, we work with hospitals and health systems across Australia to build clinical decision support systems. We’ve deployed both Claude Opus 4.7 and GPT-5.5 in production environments. We understand the regulatory landscape, the clinical workflows, and the technical challenges. If you’re ready to build clinical AI the right way, let’s talk.

The future of healthcare is AI-augmented, not AI-automated. The clinician remains the decision-maker. The AI is a tool that makes them better at their job. That’s the vision we’re building toward.